Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy GMTX Stock  Free GMTX Stock Alerts

Gemini Therapeutics (GMTX) Financials

Gemini Therapeutics logo
$49.51 -0.17 (-0.34%)
As of 05/2/2025
Compare
Annual Income Statements for Gemini Therapeutics

Annual Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -41 -36 -47 -76 -109
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109
Total Pre-Tax Income 		-41 -36 -47 -76 -109
Total Operating Income		 -34 -31 -47 -91 -130
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 31 47 91 130
Selling, General & Admin Expense		 5.87 5.76 14 22 33
Research & Development Expense		 28 25 33 69 97
Total Other Income / (Expense), net		 -6.80 -5.04 0.65 15 21
Interest Expense		 6.83 - - - 0.57
Interest & Investment Income		 0.04 0.01 0.71 15 21
Income Tax Expense		 - - 0.00 0.10 0.36
Other Gains / (Losses), net		 - - - - -0.00
Basic Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96)
Weighted Average Basic Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M
Diluted Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96)
Weighted Average Diluted Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M
Weighted Average Basic & Diluted Shares Outstanding		 15.12M 40.36M 19.00M 24.68M 34.57M

Quarterly Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -11 -23 -16 -14 -24 -27 -26 -27 -29
Consolidated Net Income / (Loss)		 -16 -11 -23 -16 -14 -24 -27 -26 -27 -29
Net Income / (Loss) Continuing Operations		 -16 -11 -23 -16 -14 -24 -27 -26 -27 -29
Total Pre-Tax Income 		-16 -11 -23 -16 -14 -24 -27 -26 -26 -29
Total Operating Income		 -10 -15 -25 -17 -19 -30 -31 -31 -33 -35
Total Operating Expenses		 10 15 25 17 19 30 31 31 33 35
Selling, General & Admin Expense		 2.59 5.01 4.95 5.23 4.54 7.15 7.76 7.37 8.17 9.75
Research & Development Expense		 7.89 10 20 12 14 23 24 23 25 25
Total Other Income / (Expense), net		 -5.67 3.78 2.37 1.41 4.86 6.17 4.52 4.56 6.37 5.27
Interest & Investment Income		 0.27 0.39 2.37 2.91 4.84 4.68 4.52 4.57 6.36 5.84
Income Tax Expense		 0.00 - 0.02 0.02 0.02 0.03 0.01 0.06 0.11 0.18
Basic Earnings per Share		 ($16.82) ($10.82) ($1.20) ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07)
Weighted Average Basic Shares Outstanding		 960.32K 1.04M 18.95M 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M
Diluted Earnings per Share		 ($16.82) ($10.82) ($1.20) ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07)
Weighted Average Diluted Shares Outstanding		 960.32K 1.04M 18.95M 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M
Basic & Diluted Earnings per Share		 - ($10.82) - - - ($1.06) - - - ($1.07)
Weighted Average Basic & Diluted Shares Outstanding		 43.33M 19.00M 19.80M 22.88M 24.14M 24.68M 24.72M 29.73M 29.76M 34.57M

Annual Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 0.45 62 107 166 -168
Net Cash From Operating Activities		 -33 -28 -42 -73 -94
Net Cash From Continuing Operating Activities		 -34 -28 -42 -73 -94
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109
Depreciation Expense		 0.32 0.03 0.09 0.10 0.16
Amortization Expense		 - - - 0.00 -5.30
Non-Cash Adjustments To Reconcile Net Income		 7.47 6.98 2.04 5.94 22
Changes in Operating Assets and Liabilities, net		 -0.73 1.43 2.44 -3.07 -1.43
Net Cash From Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292
Net Cash From Continuing Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292
Purchase of Property, Plant & Equipment		 -0.02 -0.07 -0.15 -0.09 -0.51
Purchase of Investments		 - - - 0.00 -387
Sale and/or Maturity of Investments		 - - - 0.00 95
Net Cash From Financing Activities		 34 90 149 239 218
Net Cash From Continuing Financing Activities		 34 90 149 239 218
Repayment of Debt		 0.00 0.00 0.00 0.00 -1.39
Issuance of Debt		 14 0.00 0.00 0.00 29
Issuance of Common Equity		 20 0.00 54 199 188
Other Financing Activities, net		 0.16 0.07 95 40 2.98
Cash Interest Paid		 0.35 0.00 0.00 0.00 0.20
Cash Income Taxes Paid		 - 0.00 0.00 0.11 0.30

Quarterly Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -9.69 139 42 141 -7.06 -10 -18 -62 -88 -0.20
Net Cash From Operating Activities		 -9.69 -9.67 -35 -13 -7.48 -18 -34 -15 -17 -28
Net Cash From Continuing Operating Activities		 -9.69 -9.67 -35 -13 -7.48 -18 -34 -15 -17 -28
Net Income / (Loss) Continuing Operations		 -16 -11 -23 -16 -14 -24 -27 -26 -27 -29
Consolidated Net Income / (Loss)		 -16 -11 -23 -16 -14 -24 -27 -26 -27 -29
Depreciation Expense		 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.11 0.01 0.01
Amortization Expense		 - - - - - - - - -2.50 -2.21
Non-Cash Adjustments To Reconcile Net Income		 6.22 -2.39 1.03 2.60 1.70 0.61 4.13 12 10 -4.72
Changes in Operating Assets and Liabilities, net		 0.22 3.94 -14 0.60 4.92 5.15 -11 -0.97 1.54 8.80
Net Cash From Investing Activities		 -0.02 -0.01 -0.03 -0.01 -0.05 -0.00 -0.07 -220 -71 -1.43
Net Cash From Continuing Investing Activities		 -0.02 -0.01 -0.03 -0.01 -0.05 -0.00 -0.07 -220 -71 -1.43
Purchase of Property, Plant & Equipment		 -0.02 -0.01 -0.03 -0.01 -0.05 -0.00 -0.07 0.00 0.01 -0.45
Purchase of Investments		 - - - - - - - - -94 -73
Sale and/or Maturity of Investments		 - - - - - - - - - 72
Net Cash From Financing Activities		 0.02 149 77 154 0.46 7.76 16 173 0.43 29
Net Cash From Continuing Financing Activities		 0.02 149 77 154 0.46 7.76 16 173 0.43 29
Other Financing Activities, net		 0.02 95 28 -27 0.62 38 0.81 0.57 0.40 1.20
Cash Income Taxes Paid		 - - 0.00 - 0.08 0.03 0.00 0.03 0.00 0.26

Annual Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 8.32 92 200 368 497
Total Current Assets		 5.07 90 198 366 494
Cash & Equivalents		 4.50 88 195 360 192
Short-Term Investments		 - - - 0.00 297
Prepaid Expenses		 0.56 2.45 3.88 5.28 3.73
Plant, Property, & Equipment, net		 0.29 0.11 0.17 0.17 0.75
Total Noncurrent Assets		 2.96 1.82 1.55 2.16 2.41
Other Noncurrent Operating Assets		 2.96 1.82 1.55 2.16 2.41
Total Liabilities & Shareholders' Equity		 8.32 92 200 368 497
Total Liabilities		 30 15 24 23 53
Total Current Liabilities		 25 13 23 21 23
Accounts Payable		 2.38 2.56 16 13 7.95
Accrued Expenses		 5.81 4.10 6.11 8.15 15
Other Current Liabilities		 - 6.77 0.31 0.67 0.13
Total Noncurrent Liabilities		 5.30 1.33 1.03 1.44 30
Long-Term Debt		 4.95 - - 0.00 28
Other Noncurrent Operating Liabilities		 0.35 1.33 1.03 1.44 1.55
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 78 177 345 444
Total Preferred & Common Equity		 -22 -64 177 345 444
Preferred Stock		 0.00 142 - 0.00 0.00
Total Common Equity		 -22 -64 177 345 444
Common Stock		 91 1.19 289 534 741
Retained Earnings		 -113 -65 -112 -189 -298
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.29

Quarterly Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 106 244 384 376 354 510 495
Total Current Assets		 105 242 382 374 352 508 493
Cash & Equivalents		 102 236 378 371 343 281 193
Short-Term Investments		 - - - - - 220 295
Prepaid Expenses		 2.93 5.72 4.13 3.72 9.33 7.30 5.79
Plant, Property, & Equipment, net		 0.00 0.18 0.16 0.18 0.21 0.10 0.08
Total Noncurrent Assets		 1.37 1.46 2.28 2.05 2.02 1.88 1.91
Other Noncurrent Operating Assets		 1.37 1.46 2.28 2.05 2.02 1.88 1.91
Total Liabilities & Shareholders' Equity		 106 244 384 376 354 510 495
Total Liabilities		 1.46 11 13 18 16 21 27
Total Current Liabilities		 1.46 9.98 9.68 14 15 20 25
Accounts Payable		 1.14 5.64 5.21 8.50 5.27 4.75 3.55
Accrued Expenses		 0.33 4.03 4.15 5.57 8.82 15 22
Other Current Liabilities		 - 0.31 0.32 0.35 0.77 0.76 0.08
Total Noncurrent Liabilities		 0.00 0.95 3.27 3.11 1.26 1.08 1.71
Other Noncurrent Operating Liabilities		 0.00 0.95 3.27 3.11 1.26 1.08 1.71
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 105 233 371 359 338 489 468
Total Preferred & Common Equity		 105 233 371 359 338 489 468
Total Common Equity		 105 233 371 359 338 489 468
Common Stock		 315 368 522 524 554 731 736
Retained Earnings		 -210 -135 -151 -165 -216 -242 -269
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -0.06 0.74

Annual Metrics and Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -6.60% -31.98% -91.85% -48.16%
EBIT Growth		 0.00% -5.68% -32.11% -91.70% -42.35%
NOPAT Growth		 0.00% 9.13% -53.48% -91.94% -42.35%
Net Income Growth		 0.00% 11.92% -30.19% -63.22% -43.08%
EPS Growth		 0.00% 11.92% -10.01% 92.41% -15.79%
Operating Cash Flow Growth		 0.00% 15.82% -53.45% -73.87% -27.86%
Free Cash Flow Firm Growth		 0.00% 0.00% -60.09% -159.87% -32.40%
Invested Capital Growth		 0.00% -119.79% -73.47% 15.27% -17.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 40.87% -129.18% -22.29% -9.45%
EBIT Q/Q Growth		 0.00% 41.08% -130.60% -22.26% -5.12%
NOPAT Q/Q Growth		 0.00% 49.34% -291.48% -19.22% -3.87%
Net Income Q/Q Growth		 0.00% 47.38% -167.49% -19.25% -5.68%
EPS Q/Q Growth		 0.00% 47.38% -147.12% -29.55% -14.45%
Operating Cash Flow Q/Q Growth		 0.00% 50.73% -222.81% -12.45% -11.62%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -84.47% -70.15% -10.69%
Invested Capital Q/Q Growth		 0.00% -305.43% -736.43% -31.94% 7.38%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.13% 100.33%
Interest Burden Percent		 119.94% 99.96% 98.51% 83.76% 84.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 186.80% -128.94% -36.84% -29.30% -27.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 186.80% 198.90% -16.28% -29.30% -27.73%
Return on Equity Simple (ROE_SIMPLE)		 186.80% 56.02% -26.52% -22.15% -24.65%
Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 99.25% -40.38% -9.62% -4.56% -4.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -18.48% -19.24%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -34 -36 -48 -91 -130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -36 -47 -91 -135
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.16 4.04 4.25
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.16 4.04 4.25
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 -0.99 0.00 0.00 0.00 0.06
Long-Term Debt to Equity		 -0.23 0.00 0.00 0.00 0.06
Financial Leverage		 -0.78 -1.27 -1.11 -1.06 -1.04
Leverage Ratio		 -0.38 1.81 1.15 1.09 1.10
Compound Leverage Factor		 -0.46 1.80 1.13 0.91 0.92
Debt to Total Capital		 -9,791.86% 0.00% 0.00% 0.00% 6.00%
Short-Term Debt to Total Capital		 -7,551.58% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -2,240.27% 0.00% 0.00% 0.00% 6.00%
Preferred Equity to Total Capital		 0.00% 182.68% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 9,891.86% -82.68% 100.00% 100.00% 94.00%
Debt to EBITDA		 -0.64 0.00 0.00 0.00 -0.21
Net Debt to EBITDA		 -0.51 0.00 0.00 0.00 3.42
Long-Term Debt to EBITDA		 -0.15 0.00 0.00 0.00 -0.21
Debt to NOPAT		 -0.91 0.00 0.00 0.00 -0.31
Net Debt to NOPAT		 -0.72 0.00 0.00 0.00 5.08
Long-Term Debt to NOPAT		 -0.21 0.00 0.00 0.00 -0.31
Altman Z-Score		 -31.95 3.83 0.22 36.16 20.72
Noncontrolling Interest Sharing Ratio		 0.00% 254.26% 55.79% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.20 6.74 8.79 17.06 21.17
Quick Ratio		 0.18 6.56 8.62 16.81 21.01
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -16 -26 -67 -88
Operating Cash Flow to CapEx		 -148,672.73% -40,491.18% -27,981.46% -82,541.57% -18,599.21%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -154.01
Operating Cash Flow to Interest Expense		 -4.79 0.00 0.00 0.00 -164.21
Operating Cash Flow Less CapEx to Interest Expense		 -4.79 0.00 0.00 0.00 -165.09
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -4.72 -10 -18 -15 -18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.66 -7.63 2.75 -2.71
Enterprise Value (EV)		 188 179 -166 1,034 1,425
Market Capitalization		 171 125 29 1,394 1,887
Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91
Tangible Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91
Total Capital		 -0.22 78 177 345 472
Total Debt		 22 0.00 0.00 0.00 28
Total Long-Term Debt		 4.95 0.00 0.00 0.00 28
Net Debt		 17 -88 -195 -360 -462
Capital Expenditures (CapEx)		 0.02 0.07 0.15 0.09 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.63 -11 -19 -16 -20
Debt-free Net Working Capital (DFNWC)		 -3.12 77 176 344 470
Net Working Capital (NWC)		 -20 77 176 344 470
Net Nonoperating Expense (NNE)		 17 14 14 13 19
Net Nonoperating Obligations (NNO)		 17 -88 -195 -360 -462
Total Depreciation and Amortization (D&A)		 0.32 0.03 0.09 0.10 -5.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M
Adjusted Diluted Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($53.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.35M 19.00M 24.68M 34.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -4.99 0.00 0.00 0.00 -226.78
NOPAT to Interest Expense		 -3.49 0.00 0.00 0.00 -158.75
EBIT Less CapEx to Interest Expense		 -4.99 0.00 0.00 0.00 -227.67
NOPAT Less CapEx to Interest Expense		 -3.49 0.00 0.00 0.00 -159.63
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 10.87% -176.68% -155.03% -95.86% -15.40% -142.95% -25.25% -63.52% -86.74% -30.33%
EBIT Growth		 11.02% -176.08% -154.82% -95.67% -15.38% -142.64% -25.23% -63.89% -73.38% -22.41%
NOPAT Growth		 43.20% -151.73% -152.26% -44.22% -80.91% -97.82% -25.22% -78.05% -73.31% -16.28%
Net Income Growth		 12.94% -162.20% -131.21% -66.46% 12.56% -109.70% -18.30% -65.25% -88.35% -24.93%
EPS Growth		 12.94% -152.58% 88.75% 92.70% 96.55% 90.20% 9.17% -39.19% -53.45% -0.94%
Operating Cash Flow Growth		 39.79% -149.57% -158.86% -38.39% 22.86% -84.13% 5.26% -20.98% -132.22% -54.94%
Free Cash Flow Firm Growth		 -112.03% -111.11% -119.07% 59.93% 108.85% -715.80% -19.33% -245.19% -1,446.16% 8.81%
Invested Capital Growth		 210.50% -73.47% 1.38% -654.56% -508.73% 15.27% -27.39% -89.82% -67.74% -17.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -70.73% 29.20% -116.25% 25.07% -0.60% -49.04% -11.48% 2.17% -14.88% -4.02%
EBIT Q/Q Growth		 -70.59% 29.16% -116.00% 25.04% -0.59% -48.98% -11.48% 1.90% -6.42% -5.18%
NOPAT Q/Q Growth		 12.78% -43.34% -67.27% 31.03% -9.41% -56.74% -5.88% 1.94% -6.50% -5.16%
Net Income Q/Q Growth		 -68.58% 30.38% -102.61% 30.00% 11.44% -66.97% -14.29% 2.22% -0.94% -10.74%
EPS Q/Q Growth		 -68.58% 35.67% 88.91% 38.33% 21.62% -82.76% -2.83% 5.50% 13.59% -20.22%
Operating Cash Flow Q/Q Growth		 -5.42% 0.28% -266.95% 64.12% 41.24% -138.04% -88.80% 54.19% -12.79% -58.82%
Free Cash Flow Firm Q/Q Growth		 -10.98% 77.32% -510.99% 73.94% 124.51% -2,190.71% 10.63% 24.63% 4.41% -41.62%
Invested Capital Q/Q Growth		 145.87% -736.43% 80.20% -78.95% -81.22% -31.94% 70.22% -166.64% -60.14% 7.38%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.10% 100.15% 100.14% 100.14% 100.02% 100.23% 100.43% 100.60%
Interest Burden Percent		 98.36% 96.66% 90.58% 84.55% 74.44% 83.43% 85.64% 85.18% 80.63% 84.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -14.27% -36.84% -34.69% -27.66% -27.65% -29.30% -28.23% -21.16% -25.03% -27.73%
Cash Return on Invested Capital (CROIC)		 -490.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -14.27% -16.28% -34.69% -27.66% -27.65% -29.30% -28.23% -21.16% -25.03% -27.73%
Return on Equity Simple (ROE_SIMPLE)		 -16.74% 0.00% -25.66% -17.81% -17.85% 0.00% -23.84% -18.62% -22.11% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.34 -11 -18 -12 -13 -21 -22 -22 -23 -24
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.19% -0.52% -2.95% -1.58% -0.36% -1.00% -1.70% -1.08% -0.84% -1.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -6.03% - - - -5.12%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -12 -25 -19 -19 -28 -31 -31 -33 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -12 -25 -19 -19 -28 -31 -31 -35 -37
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.68 0.16 1.73 2.37 2.99 4.04 4.55 2.28 3.12 4.25
Price to Tangible Book Value (P/TBV)		 0.68 0.16 1.73 2.37 2.99 4.04 4.55 2.28 3.12 4.25
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06
Financial Leverage		 -1.00 -1.11 -1.02 -1.01 -1.02 -1.06 -1.01 -1.02 -1.04 -1.04
Leverage Ratio		 1.07 1.15 1.07 1.04 1.04 1.09 1.05 1.04 1.05 1.10
Compound Leverage Factor		 1.05 1.11 0.97 0.88 0.77 0.91 0.90 0.89 0.85 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 94.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.42
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.08
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31
Altman Z-Score		 26.95 0.81 22.14 41.16 37.17 36.72 57.22 31.54 32.39 21.35
Noncontrolling Interest Sharing Ratio		 0.00% 55.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 71.49 8.79 24.26 39.42 25.96 17.06 23.70 25.02 19.36 21.17
Quick Ratio		 69.49 8.62 23.69 39.00 25.70 16.81 23.07 24.66 19.13 21.01
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -2.89 -18 -4.60 1.13 -24 -21 -16 -15 -21
Operating Cash Flow to CapEx		 -51,010.53% -80,541.67% -122,296.55% -106,033.33% -16,613.33% -593,200.00% -50,147.76% 0.00% 0.00% -6,140.98%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2.83 -18 -3.57 -6.38 -12 -15 -4.54 -12 -19 -18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.39 -7.63 0.05 -7.53 -14 2.75 -0.98 -5.73 -7.84 -2.71
Enterprise Value (EV)		 -31 -166 166 501 704 1,034 1,194 613 973 1,425
Market Capitalization		 71 29 403 879 1,075 1,394 1,537 1,114 1,461 1,887
Book Value per Share		 $2.42 $4.08 $5.37 $18.75 $15.69 $14.30 $13.70 $19.77 $15.74 $14.91
Tangible Book Value per Share		 $2.42 $4.08 $5.37 $18.75 $15.69 $14.30 $13.70 $19.77 $15.74 $14.91
Total Capital		 105 177 233 371 359 345 338 489 468 472
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 28
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 28
Net Debt		 -102 -195 -236 -378 -371 -360 -343 -501 -487 -462
Capital Expenditures (CapEx)		 0.02 0.01 0.03 0.01 0.05 0.00 0.07 -0.00 -0.01 0.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.46 -19 -4.26 -5.55 -11 -16 -5.52 -13 -20 -20
Debt-free Net Working Capital (DFNWC)		 103 176 232 372 360 344 337 488 468 470
Net Working Capital (NWC)		 103 176 232 372 360 344 337 488 468 470
Net Nonoperating Expense (NNE)		 8.81 0.73 5.19 3.82 0.85 2.78 4.93 4.76 3.60 5.27
Net Nonoperating Obligations (NNO)		 -102 -195 -236 -378 -371 -360 -343 -501 -487 -462
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.11 -2.49 -2.20
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.40) ($10.82) ($1.20) ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07)
Adjusted Weighted Average Basic Shares Outstanding		 1.44M 1.04M 18.95M 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M
Adjusted Diluted Earnings per Share		 ($2.40) ($10.82) ($1.20) ($0.74) ($0.58) ($1.06) ($1.09) ($1.03) ($0.89) ($1.07)
Adjusted Weighted Average Diluted Shares Outstanding		 1.44M 1.04M 18.95M 21.48M 24.32M 22.32M 24.81M 25.65M 29.94M 27.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($10.82) $0.00 $0.00 $0.00 ($1.06) $0.00 $0.00 $0.00 ($1.07)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.44M 19.00M 19.80M 22.88M 24.14M 24.68M 24.72M 29.73M 29.76M 34.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.34 -11 -18 -12 -13 -21 -22 -22 -23 -24
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Gemini Therapeutics' Financials

When does Gemini Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Gemini Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gemini Therapeutics' net income changed over the last 4 years?

Gemini Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.36 million in 2024, rising from -$40.84 million in 2020. The previous period was -$76.43 million in 2023.

What is Gemini Therapeutics's operating income?
Gemini Therapeutics's total operating income in 2024 was -$129.72 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $129.72 million
How has Gemini Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Gemini Therapeutics have?

Gemini Therapeutics' total liabilities were at $53.19 million at the end of 2024, a 132.5% increase from 2023, and a 76.2% increase since 2020.

How much cash does Gemini Therapeutics have?

In the past 4 years, Gemini Therapeutics' cash and equivalents has ranged from $4.50 million in 2020 to $360.38 million in 2023, and is currently $192.43 million as of their latest financial filing in 2024.

How has Gemini Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' book value per share changed from -1.41 in 2020 to 14.91 in 2024, a change of -1,159.3%.


Related Companies

This page (NASDAQ:GMTX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored